Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies

Toxicon

Volumn 77, Issue , 2014, Pages 114-120

  Torii, Yasushi ^a,b   Goto, Yoshitaka ^a   Nakahira, Shinji ^a   Kozaki, Shunji ^c   Ginnaga, Akihiro ^a  

^a Kaketsuken   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Osaka Prefecture University   (Japan)

Author keywords

Antibody; Botulinum toxin; ELISA; Immunogenicity; Neutralization; Rat CMAP neutralization test

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN A1; BOTULINUM TOXIN A2; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IMMUNOREACTIVITY; MOLECULAR WEIGHT; MOUSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SWINE;

ANIMALIA; ORYCTOLAGUS CUNICULUS; RATTUS; SUIDAE;

ANTIBODY; BOTULINUM TOXIN; ELISA; IMMUNOGENICITY; NEUTRALIZATION; RAT CMAP NEUTRALIZATION TEST;

ANIMALS; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXINS, TYPE A; CLOSTRIDIUM BOTULINUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEUTRALIZATION TESTS; RABBITS; RATS; SPECIES SPECIFICITY; SWINE; TOXICITY TESTS;

EID: 84889676693     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2013.11.006     Document Type: Article

References (20)

1. J.W. Arndt, M.J. Jacobson, E.E. Abola, C.M. Forsyth, W.H. Tepp, J.D. Marks, E.A. Johnson, and R.C. Stevens A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4 J. Mol. Biol. 362 4 2006 733 742 (Pubitemid 44404084)
2. S.S. Arnon Botulinum toxin as a biological weapon: medical and public health management JAMA 285 8 2001 1059 1070 (Pubitemid 32176420)
3. M.F. Brin Botulinum toxin: chemistry, pharmacology, toxicity, and immunology Muscle Nerve Suppl. 6 1997 S146 S168
4. N. Dover, J.R. Barash, and S.S. Arnon Novel Clostridium botulinum toxin gene arrangement with subtype A5 and partial subtype B3 botulinum neurotoxin genes J. Clin. Microbiol. 47 7 2009 2349 2350
5. D. Dressler, and R. Benecke Pharmacology of therapeutic botulinum toxin preparations Disabil. Rehabil. 29 23 2007 1761 1768 (Pubitemid 350176807)
6. D. Dressler, and M. Hallet Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc Eur. J. Neurol. 13 Suppl. 1 2006 11 15
7. D. Dressler Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy Eur. Neurol. 48 1 2002 26 29
8. R. Jahn, and H. Niemann Molecular mechanisms of clostridial neurotoxins Ann. N. Y. Acad. Sci. 733 1994 245 255
9. J. Jankovic Botulinum toxin in clinical practice J. Neurol. Neurosurg. Psychiatry 75 7 2004 951 957 (Pubitemid 38869604)
10. J.C. Lee, K. Yokota, H. Arimitsu, H.J. Hwang, Y. Sakaguchi, J. Cui, K. Takeshi, T. Watanabe, T. Ohyama, and K. Oguma Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin Microbiology 151 Pt 11 2005 3739 3747 (Pubitemid 41632084)
11. C. Montecucco, G. Schiavo, and O. Rossetto The mechanism of action of tetanus and botulinum neurotoxins Arch. Toxicol. Suppl. 18 1996 342 354
12. L.B. Pearce, G.E. Borodic, E.R. First, and R.D. MacCallum Measurement of botulinum toxin activity: evaluation of the lethality assay Toxicol. Appl. Pharmacol. 128 1 1994 69 77 (Pubitemid 24289132)
13. G. Sakaguchi, I. Ohishi, and S. Kozaki Purification and oral toxicities of Clostridium botulinum progenitor toxins G.E. Lewis, Biomedical Aspect of Botulism 1981 Academic Press New York 21 34
14. G. Sakagichi Clostridium botulinum toxins Pharmacol. Ther. 19 2 1983 165 194
15. L.L. Simpson The origin, structure, and pharmacological activity of botulinum toxin Pharmacol. Rev. 33 3 1981 155 188
16. S. Sugii, and G. Sakaguchi Molecular construction of Clostridium botulinum type A toxins Infect. Immun. 12 6 1975 1262 1270
17. N.S. Sadick Botulinum toxin type B Dermatol. Surg. 29 4 2003 348 351 (Pubitemid 36417446)
18. D.D. Truong, and W.H. Jost Botulinum toxin: clinical use Parkinsonism Relat. Disord. 12 6 2006 331 355 (Pubitemid 44189903)
19. Y. Torii, Y. Goto, M. Takahashi, S. Ishida, T. Harakawa, T. Sakamoto, R. Kaji, S. Kozaki, and A. Ginnaga Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins Toxicon 55 2010 407 414
20. Y. Torii, M. Takahashi, S. Ishida, Y. Goto, S. Nakahira, T. Harakawa, R. Kaji, S. Kozaki, and A. Ginnaga Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP) Toxicon 55 2010 662 665